Nicotinamide Riboside: Evidence, Safety, Dosing Ranges, and Access

Nicotinamide riboside, also called NR or Niagen, is a vitamin B3-related NAD+ precursor studied in human randomized trials for Parkinson’s disease, peripheral artery disease, and chronic kidney disease. These disease mentions describe research contexts only, not FDA-approved indications or treatment recommendations. Its evidence grade is A for trial quantity and design, but that does not prove NR works, is safe for every person, or extends human lifespan 1 2 3 4.

What it is

Nicotinamide riboside is commonly shortened to NR and is sold in some settings under the name Niagen. It is discussed in longevity research because it is connected to nicotinamide adenine dinucleotide, or NAD+, a molecule involved in cell metabolism; the supplied human evidence includes randomized trials of NR supplementation in defined disease populations, not proof of longer human life 1 2 3 4.

Names: NR, Niagen, and nicotinamide riboside

NR means nicotinamide riboside. Niagen is a name patients may see in supplement discussions. In the supplied evidence, the research records use the term nicotinamide riboside and include human randomized trials in Parkinson’s disease, peripheral artery disease, and chronic kidney disease 1 2 3 4.

How NR relates to vitamin B3 and NAD+

NR is described as a vitamin B3-related NAD+ precursor in the research and patient-education world. In plain English, that means it is studied because the body can use related B-vitamin pathways to support NAD+ biology; the supplied records, however, are clinical trial records and do not by themselves prove that raising a biomarker leads to longer life or better health in every setting 1 4.

Chia availability: Chia does not offer nicotinamide riboside

Chia does not offer nicotinamide riboside. We do offer clinician-guided NAD+ care in injection and nasal spray forms for patients who complete an online evaluation and are prescribed treatment by a licensed US provider when clinically appropriate.

Mechanism of action

NR is proposed to work through NAD+ biology, but the supplied human records mainly establish that NR has been tested in randomized clinical settings. They do not prove that any proposed mechanism explains clinical outcomes, and they do not prove human lifespan extension 1 2 3 4.

NR as an NAD+ precursor

The key idea is simple: NR is studied because it is connected to NAD+, and NAD+ is tied to energy metabolism inside cells. But a mechanism is not the same as a clinical result. The supplied Parkinson’s disease, peripheral artery disease, and chronic kidney disease trials can be used to discuss human testing, not to claim broad anti-aging effects 1 2 3 4.

Why NAD+ matters for cell metabolism

NAD+ is often discussed as a cofactor or metabolite, meaning a small molecule that helps cellular chemical reactions run 9. For a deeper plain-English overview, our guides to NAD+, NAD treatment, and NAD therapy explain why researchers study NAD+ pathways and why evidence depends on the route, formulation, population, and endpoint.

What the supplied human evidence can and cannot prove about mechanism

Human randomized trials can show whether an intervention changed measured outcomes in the studied group. They cannot automatically prove why a change happened, and they cannot be stretched into claims about all people, all doses, or lifespan. That limit matters for NR because the supplied evidence is condition-specific 1 2 3 4.

Evidence

Nicotinamide riboside has an assigned evidence grade of A — two or more human randomised controlled trials. In the supplied evidence pool, NR has been studied in randomized human trials for Parkinson’s disease, peripheral artery disease, and chronic kidney disease 1 2 3 4.

Important note: grade describes study quantity and design

An A grade does not mean NR is proven to help every patient or safe for every use. It means the supplied evidence includes at least two human randomized controlled trials. The actual question is narrower: what did each trial study, in which population, and with what endpoints 1 2 3 4?

Parkinson’s disease trials

In Parkinson’s disease, the supplied evidence includes NADPARK, a randomized phase I trial of NR supplementation, and NR-SAFE, a randomized, double-blind safety trial described as high-dose NR in Parkinson’s disease 3 4. These are human randomized trials, but their presence does not mean NR is proven for all neurologic symptoms or for people without Parkinson’s disease.

Peripheral artery disease trial evidence

For peripheral artery disease, the supplied evidence includes the NICE randomized clinical trial of nicotinamide riboside for peripheral artery disease 2. This supports saying NR has been tested in a human randomized PAD trial, not that every person with PAD should use NR or expect a specific result.

Chronic kidney disease trial evidence

For chronic kidney disease, the supplied evidence includes a randomized crossover clinical trial of coenzyme Q10 and nicotinamide riboside in chronic kidney disease 1. Because the study involved both coenzyme Q10 and NR, a reader should be careful not to assign every finding to NR alone unless the full paper supports that specific claim.

Registered trials and what is still being studied

ClinicalTrials.gov records in the supplied set show NR is being studied or has been studied in areas such as systolic heart failure, human aging interventions, exercise-related oxidative stress, cancer therapy-related cardiac dysfunction, and blood NAD+ concentration questions 5 6 7 8. Trial registration shows research activity; it does not prove benefit.

What has not been proven, including human lifespan extension

The supplied evidence does not support a claim that NR extends human lifespan. The strongest fair statement is that NR has human randomized trial evidence in specific clinical contexts, while longevity claims remain unproven in the supplied human evidence 1 2 3 4.

What studies exist

This table is retrieved from PubMed and ClinicalTrials.gov rather than assembled by hand, so it shows what is indexed — including the absences. Last retrieved 2026-09-09.

Reported dosing ranges

Reported dosing ranges should be read as research context, not personal instructions. The supplied citation records identify human NR trials and registered studies, but they do not provide numeric dose amounts in the citation strings we can cite here, so this page does not invent numbers 1 2 3 4.

Why study doses are not personal dosing advice

A study dose is chosen for a research question, with inclusion rules, exclusion rules, monitoring, and adverse-event tracking. That is different from self-selecting a supplement while managing chronic disease, prescription drugs, pregnancy, breastfeeding, cancer care, kidney disease, or neurologic disease 1 3.

When to ask a clinician before using NR

It is especially important to ask a clinician before using NR if you have chronic kidney disease, peripheral artery disease, Parkinson’s disease, cancer, pregnancy, breastfeeding, or prescription medications. Those groups either appear in the supplied clinical evidence or need closer safety review before supplement use 1 2 3 4.

Legal status

Our regulatory log holds no confirmed federal action for Nicotinamide Riboside. That means we have not found one with a primary source — not that none exists.

This section is generated from a dated log of federal actions rather than written by hand, and it is re-checked daily against the Federal Register and FDA sources. Last checked 2026-09-09. See the full legal-status tracker for every compound we follow.

Safety

Safety for NR is best understood as use-specific. The supplied evidence includes NR-SAFE, a randomized, double-blind safety trial described as high-dose nicotinamide riboside in Parkinson’s disease, but one safety trial in one population does not prove safety for every person, dose, duration, or medical condition 3.

What randomized safety trials can tell us

Randomized safety trials can track adverse events under study conditions. NR-SAFE supports saying high-dose NR safety has been evaluated in Parkinson’s disease research, while NADPARK supports saying NR supplementation has been studied in a randomized phase I Parkinson’s disease trial 3 4.

Why long-term safety is still use-specific and population-specific

Long-term safety depends on the person, condition, dose, duration, formulation, and other medications. The supplied trials do not establish safety for all people, and the registered trials show that researchers are still studying NR across different health contexts 5 6 7 8.

Who should be especially cautious

People with kidney disease, neurologic disease, peripheral artery disease, cancer care, pregnancy, or breastfeeding should be especially cautious and involve a clinician before using NR. The supplied evidence includes trials in kidney disease, Parkinson’s disease, and peripheral artery disease, which means these are medical contexts where supervision matters 1 2 3 4.

Risks of unregulated supply

A product sold as “research use only” is not the same as care guided by a licensed clinician. With unregulated supply, practical risks include identity, purity, impurity, labeling, and contamination concerns; those risks are separate from whether NR looked safe in a controlled trial setting.

Interactions

Interaction data for NR is limited in the supplied records. The provided trial citations and registry entries identify study populations and topics, but they do not provide dedicated drug-interaction studies, so absence of a listed interaction should not be read as proof of no interaction 1 2 3 4.

Chronic disease, cancer care, neurologic disease, kidney disease, pregnancy, and breastfeeding considerations

If you have chronic kidney disease, peripheral artery disease, Parkinson’s disease, cancer treatment, pregnancy, or breastfeeding, discuss NR with a clinician before using it. The supplied records include trials or registered studies involving chronic kidney disease, Parkinson’s disease, peripheral artery disease, heart failure, and cancer therapy-related cardiac dysfunction, which shows why context matters 1 2 3 4 5 8.

Medication and supplement review with a clinician

Bring a full list of prescription drugs, over-the-counter medicines, and supplements to the clinician reviewing NR. This is especially important because one supplied chronic kidney disease trial studied coenzyme Q10 and NR together, and combination use can make it harder to know which product caused which effect 1.

How to obtain it legally

Chia does not offer NR. If you are considering nicotinamide riboside for a medical condition, the safer process starts with clinician review: your diagnoses, medications, lab history, pregnancy or breastfeeding status, and goals should be reviewed before you self-prescribe a supplement.

Start with a clinician review instead of self-prescribing for a medical condition

A clinician can help decide whether NR fits the question you are trying to answer, whether a medical workup is needed first, and whether your medications or conditions raise concern. This matters because the supplied evidence is focused on specific studied populations, not general wellness claims 1 2 3 4.

What a research-chemical vendor is not

A research-chemical vendor is not a clinician evaluation, not a prescription, and not the same as a state-licensed pharmacy. It may not provide the same safeguards for identity, purity, sterility, labeling, adverse-event review, or follow-up.

How this differs from clinician-guided NAD+ care at Chia

NR and NAD+ are related topics, but they are not the same product. Chia does not offer NR. Chia does offer NAD+ injection and nasal spray, with plans currently starting at $179/mo for injection and $119/mo for nasal spray. Treatment at Chia is 100% online: a short health questionnaire is reviewed by a licensed US provider, prescriptions are issued only when clinically appropriate, and medications are compounded by state-licensed US 503A pharmacies and shipped to the patient’s door. Compounded medications are not FDA-approved, and a prescription is never guaranteed.

How does nicotinamide riboside compare with NAD+?

NR and NAD+ are connected, but they are different. NR is discussed as a precursor, while NAD+ is the molecule itself; route, formulation, evidence, and clinical oversight can differ.

If you are comparing NR with other NAD+ topics, our education pages on NAD+ supplements and NMN may help you understand the broader category. The key is not to treat all NAD-related products as interchangeable.

Keep reading

Longevity

NAD Supplement Side Effects: What Human Studies Actually Show

Longevity

NAD Therapy: What It Is, What the Evidence Shows, and What to Know Before Trying It

Longevity

NAD IV Therapy: Evidence, Safety, Side Effects, and Alternatives